Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADL NASDAQ:EPRX NASDAQ:FDMT NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$8.35+7.2%$5.47$4.35▼$8.36$570.78M-0.591.99 million shs2.53 million shsEPRXEupraxia Pharmaceuticals$7.45-0.3%$7.38$3.67▼$9.32$451.45M1.19182,795 shs94,570 shsFDMT4D Molecular Therapeutics$10.14+2.1%$9.38$3.00▼$12.34$519.09M2.77698,501 shs832,043 shsPEPGPepGen$1.76-1.7%$3.52$1.01▼$7.80$123.81M2.011.12 million shs698,753 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics0.00%+26.05%+57.37%+33.62%+72.54%EPRXEupraxia Pharmaceuticals0.00%-4.23%+8.58%-10.54%+97.10%FDMT4D Molecular Therapeutics0.00%+11.95%-1.68%+10.46%+218.27%PEPGPepGen0.00%+9.15%+7.83%-60.04%+42.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$8.35+7.2%$5.47$4.35▼$8.36$570.78M-0.591.99 million shs2.53 million shsEPRXEupraxia Pharmaceuticals$7.45-0.3%$7.38$3.67▼$9.32$451.45M1.19182,795 shs94,570 shsFDMT4D Molecular Therapeutics$10.14+2.1%$9.38$3.00▼$12.34$519.09M2.77698,501 shs832,043 shsPEPGPepGen$1.76-1.7%$3.52$1.01▼$7.80$123.81M2.011.12 million shs698,753 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics0.00%+26.05%+57.37%+33.62%+72.54%EPRXEupraxia Pharmaceuticals0.00%-4.23%+8.58%-10.54%+97.10%FDMT4D Molecular Therapeutics0.00%+11.95%-1.68%+10.46%+218.27%PEPGPepGen0.00%+9.15%+7.83%-60.04%+42.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 2.44Hold$18.00115.57% UpsideEPRXEupraxia Pharmaceuticals 2.88Moderate Buy$15.00101.34% UpsideFDMT4D Molecular Therapeutics 2.67Moderate Buy$29.88194.63% UpsidePEPGPepGen 2.67Moderate Buy$11.80570.45% UpsideCurrent Analyst Ratings BreakdownLatest PEPG, EPRX, FDMT, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026FDMT4D Molecular Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/7/2026EPRXEupraxia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/4/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/22/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026EPRXEupraxia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CADLCandel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026FDMT4D Molecular Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CADLCandel Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight4/7/2026CADLCandel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/31/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $5.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/AFDMT4D Molecular Therapeutics$85.21M6.22N/AN/A$8.85 per share1.15PEPGPepGenN/AN/AN/AN/A$2.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$38.18M-$0.71N/AN/AN/AN/A-51.44%-36.31%5/12/2026 (Estimated)EPRXEupraxia Pharmaceuticals-$38.58M-$1.03N/AN/AN/AN/A-167.68%-66.72%5/12/2026 (Estimated)FDMT4D Molecular Therapeutics-$140.11M-$2.57N/AN/AN/A-182.34%-37.26%-32.96%N/APEPGPepGen-$89.65M-$2.41N/AN/AN/AN/A-75.73%-60.42%5/14/2026 (Estimated)Latest PEPG, EPRX, FDMT, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026PEPGPepGen-$0.31N/AN/AN/AN/AN/A5/12/2026Q1 2026CADLCandel Therapeutics-$0.2958N/AN/AN/AN/AN/A5/12/2026N/AEPRXEupraxia Pharmaceuticals-$0.22N/AN/AN/AN/AN/A5/7/2026Q1 2026FDMT4D Molecular Therapeutics-$0.97-$1.01-$0.04-$1.01$2.59 million$3.05 million3/19/2026Q4 2025EPRXEupraxia Pharmaceuticals-$0.16-$0.37-$0.21-$0.37N/AN/A3/18/2026Q4 2025FDMT4D Molecular Therapeutics-$0.53$0.43+$0.96$0.43$30.86 million$85.09 million3/12/2026Q4 2025CADLCandel Therapeutics-$0.24-$0.54-$0.30-$0.54N/AN/A3/4/2026Q4 2025PEPGPepGen-$0.40-$0.27+$0.13-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.9113.4913.49EPRXEupraxia PharmaceuticalsN/A15.1215.12FDMT4D Molecular TherapeuticsN/A9.399.39PEPGPepGenN/A11.9411.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%EPRXEupraxia PharmaceuticalsN/AFDMT4D Molecular Therapeutics99.27%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%EPRXEupraxia PharmaceuticalsN/AFDMT4D Molecular Therapeutics9.60%PEPGPepGen5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6073.27 million61.11 millionOptionableEPRXEupraxia Pharmaceuticals2960.43 millionN/AN/AFDMT4D Molecular Therapeutics12052.28 million47.26 millionOptionablePEPGPepGen3069.17 million65.57 millionNot OptionablePEPG, EPRX, FDMT, and CADL HeadlinesRecent News About These CompaniesPepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 8 at 4:55 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMay 7 at 10:00 AM | prnewswire.comPepGen (PEPG) Projected to Post Earnings on ThursdayMay 7 at 3:48 AM | marketbeat.comPictet Asset Management Holding SA Purchases 871,059 Shares of PepGen, Inc. $PEPGMay 3, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)April 26, 2026 | theglobeandmail.comStifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)April 26, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 16, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 14, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 9, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 7, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comPepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some ReliefMarch 31, 2026 | seekingalpha.comPepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseMarch 31, 2026 | biospace.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMarch 31, 2026 | globenewswire.comPepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMarch 31, 2026 | globenewswire.comPepGen crashes after mid-stage trial data for muscle disorder therapyMarch 31, 2026 | msn.comPepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data TranscriptMarch 31, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePEPG, EPRX, FDMT, and CADL Company DescriptionsCandel Therapeutics NASDAQ:CADL$8.35 +0.56 (+7.19%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$8.33 -0.02 (-0.29%) As of 05/8/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Eupraxia Pharmaceuticals NASDAQ:EPRX$7.45 -0.02 (-0.27%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$7.70 +0.25 (+3.36%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.4D Molecular Therapeutics NASDAQ:FDMT$10.14 +0.21 (+2.11%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$10.24 +0.10 (+0.99%) As of 05/8/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.PepGen NASDAQ:PEPG$1.76 -0.03 (-1.68%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.74 -0.01 (-0.85%) As of 05/8/2026 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
